title: Tenofovir alafenamide for HIV infection: is less more?
authors.affiliation: Department of Medicine, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
authors.forename: Christina
authors.initials: C
authors.lastname: Wyatt
authors.affiliation: Departments of Global Health, Medicine, and Epidemiology, University of Washington, Seattle, WA 98104, USA. Electronic address: jbaeten@uw.edu.
authors.forename: Jared M
authors.initials: JM
authors.lastname: Baeten
mesh_terms: D000225:Adenine / Q000008:administration & dosage / Q000031:analogs & derivatives*; D000409:Alanine; D019380:Anti-HIV Agents / Q000627:therapeutic use*; D002219:Carbamates / Q000008:administration & dosage*; D000069547:Cobicistat; D003841:Deoxycytidine / Q000008:administration & dosage / Q000031:analogs & derivatives*; D000068679:Emtricitabine; D005260:Female; D015658:HIV Infections / Q000188:drug therapy*; D006801:Humans; D008297:Male; D063065:Organophosphonates / Q000008:administration & dosage*; D015363:Quinolones / Q000008:administration & dosage*; D000068698:Tenofovir / Q000031:analogs & derivatives; D013844:Thiazoles / Q000008:administration & dosage*
chemical_list: D019380:Anti-HIV Agents; D002219:Carbamates; D063065:Organophosphonates; D015363:Quinolones; D013844:Thiazoles; D003841:Deoxycytidine; C509700:elvitegravir; D000068698:Tenofovir; C442442:tenofovir alafenamide; D000068679:Emtricitabine; D000225:Adenine; D000069547:Cobicistat; D000409:Alanine